Selank: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 18 sources cited

Overview

Selank is a synthetic analog of the naturally occurring immunomodulatory peptide tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is approved in Russia as an anxiolytic and nootropic medication. Selank combines potent anti-anxiety effects with cognitive enhancement and immune modulation, making it one of the most versatile peptides in the research community. Unlike benzodiazepines, it reduced anxiety in animal tests without the sedation and motor impairment they cause; dependence has not been tested in people.

Mechanism of Action

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a heptapeptide based on the tuftsin sequence (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro stabilizing tail that dramatically increases its biological half-life. Its mechanism of action is multifaceted and involves several key neurochemical systems. First, Selank modulates the GABAergic system — it acts as a positive allosteric modulator of GABA binding at a site that appears to differ from, but may partly overlap, the benzodiazepine site, and it produced anxiolysis without sedation in animal tests. This is a critical distinction from classical anxiolytics. Second, Selank profoundly influences monoamine neurotransmission. It stabilizes enkephalin degradation by inhibiting enkephalinase enzymes, increasing endogenous opioid peptide levels in the brain. It also modulates serotonin metabolism, increasing serotonin turnover in the cortex and shifting the levels of dopamine and serotonin metabolites in a strain-dependent way. Third, Selank is a potent neurotrophin modulator. It regulates brain-derived neurotrophic factor (BDNF) expression in the rat hippocampus, supporting neuroplasticity, long-term potentiation, and memory consolidation. Gene expression studies found 36 genes changed more than twofold in the rat hippocampus after a single intranasal dose, most of them encoding membrane proteins, and 45 of 84 neurotransmission genes changed in the frontal cortex. Fourth, as a tuftsin derivative, Selank retains significant immunomodulatory properties. It suppressed IL-6 gene expression in blood cells from patients, shifted the balance of Th1 and Th2 cytokines in patients treated for 14 days, and induced interferon-alpha genes in mice without changing TNF-α. This dual anxiolytic-immunomodulatory profile is unique among available peptides.

Selank Benefits: What the Research Shows

  • A 2008 randomised trial in Zhurnal Nevrologii i Psikhiatrii found Selank matched the benzodiazepine medazepam for anxiety in 62 patients, and also eased asthenia
  • Gene expression profiling found 45 of 84 neurotransmission genes changed in the rat frontal cortex an hour after Selank (Frontiers in Pharmacology, 2016)
  • Russian clinical trials reported improvement in anxiety and somatoform disorders, with the anxiolytic effect still present a week after the last dose
  • Intranasal Selank changed BDNF expression in the rat hippocampus (Doklady Biological Sciences, 2008)
  • A study in Zhurnal Nevrologii i Psikhiatrii reported mild nootropic effects alongside anxiolysis in patients treated for anxiety disorders
  • Immunological studies show Selank suppressed IL-6 gene expression in blood cells from patients and induced interferon-alpha genes in mice, with no change in IL-4, IL-10 or TNF-α
  • Resting-state imaging in 52 healthy volunteers found Selank and Semax altered connectivity between the right amygdala and the right temporal cortex (Doklady Biological Sciences, 2020)

Selank Dosage

  • Intranasal administration: 200–400 mcg per nostril, 2–3 times daily (most common route)
  • Subcutaneous injection: 250–500 mcg once or twice daily
  • Russian clinical studies used 14-day intranasal courses, though the published abstracts do not state the daily dose
  • Cycle: 14–30 days on, 2–4 weeks off, though some users report sustained benefits with continuous use
  • Start with lower doses (200 mcg) and titrate up based on response
  • Effects are noticeable within 15–30 minutes of intranasal administration
  • For acute anxiety, a single 400 mcg intranasal dose can be used as needed
  • Some pair it with NA-Selank-Amidate, though no published study compares the two forms
  • No food timing restrictions; can be taken at any time of day
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Selank Side Effects & Safety

Known Side Effects

  • Generally well tolerated in the small Russian trials published so far, which recorded few side effects
  • Mild nasal irritation or dryness with intranasal administration (the most commonly reported complaint)
  • Transient fatigue in sensitive individuals, particularly at higher doses
  • Rare reports of mild headache, usually resolving within hours
  • Published clinical studies have not reported sedation, cognitive impairment or withdrawal, but they were small and short, and dependence has not been formally tested
  • No sexual side effects reported, unlike SSRIs
  • Theoretical immune stimulation may be contraindicated in autoimmune conditions

Safety Profile

Selank has been tested in Russian clinical trials of 60 to 70 patients and is approved as a pharmaceutical product (marketed as Selank nasal drops) for anxiety and cognitive disorders. Published clinical trials, all small, report no significant adverse effects. Dependence, withdrawal and interaction with alcohol or other sedatives have not been tested in people, and in animals Selank did change the effects of both diazepam and ethanol. Unlike benzodiazepines, it does not impair motor function, reaction time, or cognitive performance. No acute toxicity figure for Selank was found in the published literature. However, because it modulates immune function, caution is advised in patients with autoimmune disorders, organ transplants, or those taking immunosuppressive medications. Selank has not been extensively studied in pregnancy or lactation. Drug interactions have not been studied in people. The compound is not regulated as a controlled substance in most jurisdictions.

What to Expect

First dose (within 15–30 minutes): A subtle but noticeable sense of calm settles in. Anxious mental chatter quiets without any sedation or mental dulling. Many users describe it as 'the volume being turned down on worry.' Week 1: Consistent anxiolytic effects become more prominent. Social interactions feel easier, and stress responses are more measured. Cognitive clarity improves — thoughts feel more organized and focused. Sleep quality often improves as background anxiety decreases. Week 2–3: Full effects manifest. Users typically report improved verbal fluency, better working memory, enhanced creativity, and a stable, positive mood. The immune-modulating effects may become apparent as reduced susceptibility to minor infections during stressful periods. Week 4+: Benefits appear to sustain and may persist for 1–2 weeks after discontinuation, suggesting neuroplastic changes rather than purely acute receptor effects. No tolerance development is reported even with extended use.

Common Stacks

Storage & Handling

Store lyophilized Selank at 2–8°C for up to 24 months. For long-term storage, -20°C is preferred. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 30 days. Intranasal spray preparations should be kept refrigerated and used within 2–4 weeks of preparation. Protect from light. The peptide is relatively stable but degrades in the presence of heat and repeated freeze-thaw cycles.

Pricing & Available Variants

$33price range
10mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008.
  2. Medvedev VE, Tereshchenko ON, Israelian AIu, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014.
  3. Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015.
  4. Zozulya AA, Kost NV, Yu Sokolov O, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001.
  5. Kost NV, Sokolov OIu, Gabaeva MV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum]. Bioorg Khim. 2001.
  6. Vyunova TV, Andreeva L, Shevchenko K, et al. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018.
  7. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016.
  8. Kolomin TA, Agapova TIu, Agniullin IaV, et al. Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank. Zh Vyssh Nerv Deiat Im I P Pavlova. 2013.
  9. Seredenin SB, Kozlovskaia MM, Blednov IuA, et al. The anxiolytic action of an analog of the endogenous peptide tuftsin on inbred mice with different phenotypes of the emotional stress reaction. Zh Vyssh Nerv Deiat Im I P Pavlova. 1998.
  10. Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008.
  11. Kolik LG, Nadorova AV, Antipova TA, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bull Exp Biol Med. 2019.
  12. Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008.
  13. Ershov FI, Uchakin PN, Uchakina ON, et al. Antiviral activity of immunomodulator Selank in experimental influenza infection. Vopr Virusol. 2009.
  14. Panikratova YR, Lebedeva IS, Sokolov OY, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020.
  15. Doyno CR, White CM. Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. J Clin Pharmacol. 2021.
  16. Boĭko SS, Zherdev VP, Dvorianinov AA, et al. The pharmacokinetics and metabolism of heptapeptide--a prospective synthetic analog of tuftsin with psychostimulating action in rats. Eksp Klin Farmakol. 1998.
  17. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017.
  18. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.

Related Peptides

Track Selank in Your Protocol

Log your Selank doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free